Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis

Stallergenes Greer307 enrolled

Overview

Safety and tolerability of ORALAIR in children 5 to 9 years of age during the first 30 days of treatment.

The purpose of this study is to further describe the safety and tolerability of ORALAIR tablets in children 5 to 9 years of age with grass-pollen-induced allergic rhinitis with or without conjunctivitis. Patients are followed for safety and tolerability during the first 30 treatment days.

Study Type

OBSERVATIONAL

Enrollment

307

Conditions

Allergy

Interventions

OralairDRUG

Observational study, Oralair is used as prescribed by the prescriber phycisian.

Eligibility

Sex: ALLMin age: 5 YearsMax age: 9 Years

Medical Language ↔ Plain English

Inclusion Criteria: Allergen immunotherapy naive male or female outpatients aged 5 to 9 years (inclusive) prescribed ORALAIR. Exclusion Criteria: Patients already participating in a clinical trial.

Locations (1)

Klinikum Augsburg, Klinik für Kinder und Jugendliche

Augsburg, Bavaria, Germany

Outcomes

Primary Outcomes

All adverse events that started on or after the day the first dose of Oralair

Time frame: During 30 days after the date of the first dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.